^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

Published date:
01/20/2021
Excerpt:
The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide.
DOI:
10.1021/acs.jmedchem.0c01563